BMO Capital lowered the firm’s price target on Doximity (DOCS) to $25 from $45 and keeps a Market Perform rating on the shares. Near term headwinds are weighing on the company’s Q4 outlook but should reverse course across 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $50 from $80 at BTIG
- Doximity price target lowered to $55 from $75 at Needham
- Doximity price target lowered to $40 from $70 at Piper Sandler
- Doximity price target lowered to $45 from $55 at Wells Fargo
- Doximity: Rebounding Pharma Momentum, Emerging AI Upside, and Attractive Valuation Support Renewed Growth Buy Thesis